Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Different morphological structures of breast tumors demonstrate individual drug resistance gene expression profiles.

Gerashchenko TS, Denisov EV, Novikov NM, Tashireva LA, Kaigorodova EV, Savelieva OE, Zavyalova MV, Cherdyntseva NV, Perelmuter VM.

Exp Oncol. 2018 Oct;40(3):228-234.

PMID:
30285010
2.

MT1-MMP targeting to endolysosomes is mediated by upregulation of flotillins.

Planchon D, Rios Morris E, Genest M, Comunale F, Vacher S, Bièche I, Denisov EV, Tashireva LA, Perelmuter VM, Linder S, Chavrier P, Bodin S, Gauthier-Rouvière C.

J Cell Sci. 2018 Sep 5;131(17). pii: jcs218925. doi: 10.1242/jcs.218925.

PMID:
30111578
3.

The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.

Visweshwaran SP, Thomason PA, Guerois R, Vacher S, Denisov EV, Tashireva LA, Lomakina ME, Lazennec-Schurdevin C, Lakisic G, Lilla S, Molinie N, Henriot V, Mechulam Y, Alexandrova AY, Cherdyntseva NV, Bièche I, Schmitt E, Insall RH, Gautreau A.

EMBO J. 2018 Jul 2;37(13). pii: e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.

PMID:
29844016
4.

Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer.

Kaigorodova EV, Savelieva OE, Tashireva LA, Tarabanovskaya NA, Simolina EI, Denisov EV, Slonimskaya EM, Choynzonov EL, Perelmuter VM.

Molecules. 2018 Mar 22;23(4). pii: E727. doi: 10.3390/molecules23040727.

5.

A fixed partial epithelial-mesenchymal transition (EMT) triggers carcinogenesis, whereas asymmetrical division of hybrid EMT cells drives cancer progression.

Denisov EV, Perelmuter VM.

Hepatology. 2018 Sep;68(3):807-810. doi: 10.1002/hep.29784. Epub 2018 May 14. No abstract available.

PMID:
29331068
6.

Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44+CD24- stemness.

Denisov EV, Skryabin NA, Gerashchenko TS, Tashireva LA, Wilhelm J, Buldakov MA, Sleptcov AA, Lebedev IN, Vtorushin SV, Zavyalova MV, Cherdyntseva NV, Perelmuter VM.

Oncotarget. 2017 May 19;8(37):61163-61180. doi: 10.18632/oncotarget.18022. eCollection 2017 Sep 22.

7.

Types of Immune-Inflammatory Responses as a Reflection of Cell-Cell Interactions under Conditions of Tissue Regeneration and Tumor Growth.

Tashireva LA, Perelmuter VM, Manskikh VN, Denisov EV, Savelieva OE, Kaygorodova EV, Zavyalova MV.

Biochemistry (Mosc). 2017 May;82(5):542-555. doi: 10.1134/S0006297917050029. Review.

PMID:
28601064
8.

Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity.

Gerashchenko TS, Zavyalova MV, Denisov EV, Krakhmal NV, Pautova DN, Litviakov NV, Vtorushin SV, Cherdyntseva NV, Perelmuter VM.

Acta Naturae. 2017 Jan-Mar;9(1):56-67.

9.

Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects.

Cherdyntseva NV, Litviakov NV, Denisov EV, Gervas PA, Cherdyntsev ES.

Exp Oncol. 2017 Mar;39(1):2-11. Review.

PMID:
28361862
10.

Effect of small and radical surgical injury on the level of different populations of circulating tumor cells in the blood of breast cancer patients.

Kaigorodova EV, Tarabanovskaya NA, Staheeva MN, Savelieva OE, Tashireva LA, Denisov EV, Perelmuter VM.

Neoplasma. 2017;64(3):437-443. doi: 10.4149/neo_2017_315.

PMID:
28253723
11.

Intratumoral heterogeneity of macrophages and fibroblasts in breast cancer is associated with the morphological diversity of tumor cells and contributes to lymph node metastasis.

Tashireva LA, Denisov EV, Gerashchenko TS, Pautova DN, Buldakov MA, Zavyalova MV, Kzhyshkowska J, Cherdyntseva NV, Perelmuter VM.

Immunobiology. 2017 Apr;222(4):631-640. doi: 10.1016/j.imbio.2016.11.012. Epub 2016 Nov 27.

PMID:
27916281
12.

Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium.

Pankova OV, Denisov EV, Ponomaryova AA, Gerashchenko TS, Tuzikov SA, Perelmuter VM.

Tumour Biol. 2016 Mar;37(3):3599-607. doi: 10.1007/s13277-015-4196-2. Epub 2015 Oct 11.

PMID:
26456960
13.

Cancer Invasion: Patterns and Mechanisms.

Krakhmal NV, Zavyalova MV, Denisov EV, Vtorushin SV, Perelmuter VM.

Acta Naturae. 2015 Apr-Jun;7(2):17-28.

14.

Relationship between morphological and cytogenetic heterogeneity in invasive micropapillary carcinoma of the breast: a report of one case.

Denisov EV, Skryabin NA, Vasilyev SA, Gerashchenko TS, Lebedev IN, Zavyalova MV, Cherdyntseva NV, Perelmuter VM.

J Clin Pathol. 2015 Sep;68(9):758-62. doi: 10.1136/jclinpath-2015-203009. Epub 2015 Jun 15. No abstract available.

PMID:
26076966
15.

Invasive and drug resistant expression profile of different morphological structures of breast tumors.

Denisov EV, Gerashchenko TS, Zavyalova MV, Litviakov NV, Tsyganov MM, Kaigorodova EV, Slonimskaya EM, Kzhyshkowska J, Cherdyntseva NV, Perelmuter VM.

Neoplasma. 2015;62(3):405-11. doi: 10.4149/neo_2015_041.

PMID:
25672673
16.

The phenomenon of multi-drug resistance in the treatment of malignant tumors.

Vtorushin SV, Khristenko KY, Zavyalova MV, Perelmuter VM, Litviakov NV, Denisov EV, Dulesova AY, Cherdyntseva NV.

Exp Oncol. 2014 Sep;36(3):144-56. Review.

PMID:
25265346
17.

Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression.

Denisov EV, Litviakov NV, Zavyalova MV, Perelmuter VM, Vtorushin SV, Tsyganov MM, Gerashchenko TS, Garbukov EY, Slonimskaya EM, Cherdyntseva NV.

Sci Rep. 2014 Apr 16;4:4709. doi: 10.1038/srep04709.

18.

Intratumor heterogeneity: nature and biological significance.

Gerashchenko TS, Denisov EV, Litviakov NV, Zavyalova MV, Vtorushin SV, Tsyganov MM, Perelmuter VM, Cherdyntseva NV.

Biochemistry (Mosc). 2013 Nov;78(11):1201-15. doi: 10.1134/S0006297913110011. Review.

PMID:
24460935
19.

[Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].

Litviakov NV, Garbukov EIu, Slonimskaia EM, Tsyganov MM, Denisov EV, Vtorushin SV, Khristenko KIu, Zav'ialova MV, Cherdyntseva NV.

Vopr Onkol. 2013;59(3):334-40. Russian.

PMID:
23909034
20.

Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified.

Zavyalova MV, Denisov EV, Tashireva LA, Gerashchenko TS, Litviakov NV, Skryabin NA, Vtorushin SV, Telegina NS, Slonimskaya EM, Cherdyntseva NV, Perelmuter VM.

Biores Open Access. 2013 Apr;2(2):148-54. doi: 10.1089/biores.2012.0278.

21.

Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response.

Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV, Vtorushin SV, Zavyalova MV, Slonimskaya EM, Perelmuter VM.

Cancer Chemother Pharmacol. 2013 Jan;71(1):153-63. doi: 10.1007/s00280-012-1992-x. Epub 2012 Oct 2.

PMID:
23053273
22.

The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis.

Zavyalova MV, Perelmuter VM, Vtorushin SV, Denisov EV, Litvyakov NV, Slonimskaya EM, Cherdyntseva NV.

Diagn Cytopathol. 2013 Mar;41(3):279-82. doi: 10.1002/dc.21852. Epub 2011 Nov 18. No abstract available.

PMID:
22102485
23.

Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis.

Cherdyntseva NV, Denisov EV, Litviakov NV, Maksimov VN, Malinovskaya EA, Babyshkina NN, Slonimskaya EM, Voevoda MI, Choinzonov EL.

DNA Cell Biol. 2012 Mar;31(3):306-16. doi: 10.1089/dna.2011.1351. Epub 2011 Aug 12.

PMID:
21838531
24.

Coordination of TP53 abnormalities in breast cancer: data from analysis of TP53 polymorphisms, loss of heterozygosity, methylation, and mutations.

Denisov EV, Sukhanovskaya TV, Dultseva TS, Malinovskaya EA, Litviakov NV, Slonimskaya EM, Choinzonov EL, Cherdyntseva NV.

Genet Test Mol Biomarkers. 2011 Dec;15(12):901-7. doi: 10.1089/gtmb.2011.0038. Epub 2011 Aug 2.

PMID:
21810023
25.

Age-related function of tumor suppressor gene TP53:contribution to cancer risk and progression.

Cherdyntseva NV, Gervas PA, Litvyakov NV, Stakcheeva MN, Ponomaryeva AA, Dobrodeev AY, Denisov EV, Belyavskaya VA, Choinzonov EL.

Exp Oncol. 2010 Sep;32(3):205-8.

PMID:
21403619
26.

Association between TP53 gene ARG72PRO polymorphism and chromosome aberrations in human cancers.

Litviakov NV, Denisov EV, Takhauov RM, Karpov AB, Skobel'skaja EV, Vasil'eva EO, Goncharik OO, Ageeva AM, Mamonova NV, Mezheritskiy SA, Sevost'janova NV, Koshel AP.

Mol Carcinog. 2010 Jun;49(6):521-4. doi: 10.1002/mc.20633.

PMID:
20512840
27.

[Association study of the SCN1 gene polymorphism and effective dose of lamotrigine].

Krikova EV, Val'dman EA, Avakian GN, Andreev IaA, Denisov EV, Rider FK, Biktimerov RR, Chukanova AS, Burd SG.

Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(10):57-62. Russian.

PMID:
20037572
28.

TP53 mutations and Arg72Pro polymorphism in breast cancers.

Denisov EV, Cherdyntseva NV, Litvyakov NV, Slonimskaya EM, Malinovskaya EA, Voevoda MI, Belyavskaya VA, Stegniy VN.

Cancer Genet Cytogenet. 2009 Jul 15;192(2):93-5. doi: 10.1016/j.cancergencyto.2009.03.014. No abstract available.

PMID:
19596263
29.

[Genetic and clinical and pathological characteristics of breast cancer in premenopausal and postmenopausal women].

Perel'muter VM, Zav'ialova MV, Vtorushin SV, Slonimskaia EM, Kritskaia NG, Garbukov EIu, Litviakov NV, Stakheeva MN, Babyshkina NN, Malinovskaia EA, Denisov EV, Grigor'eva ES, Nazarenko MS, Sennikov SV, Goreva EP, Kozlov VA, Voevoda MI, Maksimov VN, Beliavskaia VA, Cherdyntseva NV.

Adv Gerontol. 2008;21(4):643-53. Russian.

PMID:
19432218
30.

Surface-induced dissociation in a Fourier transform ion cyclotron resonance mass spectrometer: instrument design and evaluation.

Laskin J, Denisov EV, Shukla AK, Barlow SE, Futrell JH.

Anal Chem. 2002 Jul 15;74(14):3255-61.

PMID:
12139026
31.

Supplemental Content

Loading ...
Support Center